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Metformin inhibits hepatocellular 
glucose, lipid and cholesterol 
biosynthetic pathways by 
transcriptionally suppressing 
steroid receptor coactivator 2 
(SRC-2)
Andre Madsen1,2, Olivera Bozickovic1,2, Jan-Inge Bjune1,2, Gunnar Mellgren1,2,3 & 
Jørn V. Sagen1,2,3
The ability of the anti-diabetic drug metformin to inhibit anabolic processes including 
gluconeogenesis and lipogenesis is partly attributable to activation of the AMP-activated protein 
kinase (AMPK) pathway. The p160 steroid receptor coactivator 2 (SRC-2) is a key regulator of cellular 
metabolism and drives expression of the gluconeogenic enzyme glucose-6-phosphatase (G6Pc). Here, 
we uncovered a role for SRC-2 in the metabolic reprogramming imposed by metformin. In FaO cells, 
metformin dose-dependently reduced mRNA expression of SRC-2. Microarray analysis of metformin-
treated cells revealed an overrepresentation of downregulated genes involved in biosynthesis of 
lipids and cholesterol. Several metformin-regulated genes including fatty acid synthase (FASN) 
were validated as transcriptional targets of SRC-2 with promoters characterized by sterol regulatory 
element (SRE) binding protein (SREBP) recognition sequences. Transactivation assays of the 
FASN promoter confirmed that SRC-2 is a coactivator of SREBP-1. By suppressing SRC-2 at the 
transcriptional level, metformin impeded recruitment of SRC-2 and RNA polymerase II to the G6Pc 
promoter and to SREs of mutual SRC-2/SREBP-1 target gene promoters. Hepatocellular fat accretion 
was reduced by metformin or knock-down of both SRC-2 and SREBP-1. Accordingly we propose that 
metformin inhibits glucose and lipid biosynthesis partly by downregulating SRC-2 gene expression.
The p160 steroid receptor coactivator (SRC) family consists of the three distinct members SRC-1/
NCOA1, SRC-2/NCOA2/GRIP1/TIF2 and SRC-3/NCOA3/AIB1 that aid in the function of nuclear hor-
mone receptors and transcriptional regulation of target genes. The SRCs thus regulate metabolism and a 
variety of cellular processes by facilitating transcription of hormonally regulated target genes1–3. SRC-2 
regulates physiology and metabolism in a tissue-specific manner and is accordingly subject to regula-
tion by several cell signaling pathways and even circadian events4–7. Previous studies have demonstrated 
that SRC-2 contributes to obesity and insulin resistance8, fat accretion4,7, hepatic gluconeogenesis9,10 and 
biosynthesis of lipids4,9,10 and cholesterol6,9,10 at the transcriptional level. It has previously been shown 
that SRC-2 liver knock-out mice exhibit fasting hypoglycemia due to reduced hepatic expression of the 
rate-limiting gluconeogenic enzyme glucose-6-phosphatase (G6pc)10. This observation was coupled with 
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the finding that SRC-2 acts as a coactivator of the orphan nuclear receptor RAR-related orphan receptor 
alpha (RORα ) on the proximal G6pc promoter10. Microarray profiling of liver from SRC-2 knock-out 
mice revealed reduced expression of Srebp1 and several key metabolic enzymes involved in gluconeo-
genesis (G6pc), lipogenesis (Fasn, Elovl6) and cholesterol synthesis (Hmgcr, Hmgcs1, Nsdhl, Cyp51)11. 
Notably, the sterol regulatory element binding protein 1 (SREBP-1) represents a master regulator of 
biosynthesis of lipids and cholesterol12. It was recently demonstrated that SRC-2 is activated in response 
to phosphorylation by the nutrient-sensor mammalian target of rapamycin complex 1 (mTORC1) and 
this event enables SRC-2 coactivation of SREBP-1 to promote lipogenesis and survival of particularly 
lipid-reliant prostate cancer cell models4.
Metformin, a synthetic biguanide drug, remains the preferred pharmacologic treatment for type 2 
diabetes13,14. The ability of metformin to suppress hepatic gluconeogenesis and other anabolic pathways 
including lipid and cholesterol biosynthesis is partly attributed to transient inhibition of the mitochon-
drial respiratory chain complex I and indirect activation of the energy-sensing AMP-activated protein 
kinase (AMPK) pathway15–17. Administration of metformin is associated with activation of AMPK and 
transcriptional repression of hepatic gluconeogenic enzymes18. Furthermore, AMPK inhibits lipogene-
sis by reducing activity of acetyl-CoA carboxylase14 and downregulating SREBP-1 and its target genes 
including fatty acid synthase (FASN)19. Several studies also support a role for metformin in the treat-
ment of non-alcoholic fatty liver disease (NAFLD)20–23. The pleiotropic AMPK pathway regulates cellular 
energy balance by modulating metabolism and this is partly achieved by inhibition of mTORC1 activ-
ity16,24. Interestingly, metformin-induced inhibition of both mTORC1 activity and gluconeogenic gene 
expression is retained in the absence of the catalytic AMPK subunits25,26. Thus, unlike the AMP analogue 
5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), the precise mechanisms by which metformin 
exerts its effects on hepatocyte metabolism remain elusive and several reports suggest that the central 
therapeutic properties of metformin in fact are mediated independently of the AMPK pathway25,27–29.
Liver knock-out SRC-2 mice are characterized by reduced expression of rate-limiting enzymes per-
taining to gluconeogenesis and biosynthesis of lipids and cholesterol4,6,9. This study aimed to determine 
whether the seemingly overlapping metabolic alterations induced by metformin may involve a down-
regulation of SRC-2.
Results
Metformin inhibits expression of SRC-2. The established effects of metformin on hepatocellular 
metabolism led us to investigate whether metformin affects the expression of members of the steroid 
receptor coactivator family. The effects of increasing doses of metformin on relative expression levels of 
the steroid receptor coactivators SRC-1, SRC-2 and SRC-3 were assessed in the rat FaO hepatoma cell 
line (Fig. 1a). Whereas mRNA levels of SRC-1 and SRC-3 remained essentially unchanged in response 
to treatment with metformin, we observed a dose-dependent downregulation of SRC-2 mRNA. This 
range of metformin concentration (0–5 mM) was not cytotoxic to the cells and did not significantly affect 
mRNA levels of the house-keeping gene Rpl4. Expression levels of the gluconeogenic enzyme G6pc was 
included as positive control of the pharmacological effect of metformin. Since metformin significantly 
reduced SRC-2 mRNA we next investigated whether this downregulation also would affect endogenous 
SRC-2 protein level (Fig. 1b). As confirmed by densitometry of Western blots from three independent 
experiments, metformin concentrations at or above 1 mM caused a significant reduction of SRC-2 pro-
tein relative to beta-Actin (ACTB) in FaO cells. The above findings were replicated in HepG2 cells (data 
not shown). HepG2 cells were used for transactivation assays due to more effective plasmid transfection. 
Transactivation of a luciferase reporter construct under transcriptional control of the endogenous SRC-2 
promoter (containing bases − 1500 to + 1 relative to the SRC-2 transcription start site) was used to detect 
whether metformin downregulates SRC-2 at the transcriptional level. This reporter was dose-dependently 
inhibited by metformin relative to the control pGL-basic reporter (Fig. 1c). Taken together, these results 
demonstrate that treatment of cells with metformin decreases SRC-2 mRNA and protein levels.
Metformin inhibits transcription of SRC-2 target genes involved in biosynthesis of lipids and 
cholesterol. In order to elucidate how metformin affects the hepatocellular transcriptome we per-
formed a significance analysis of microarray based on FaO cells treated with vehicle or 5 mM metformin 
and categorized the genes into respective biological processes using the PANTHER database (Fig.  2). 
As expected, mainly genes related to metabolic processes were differentially regulated by metformin 
and among the upregulated genes there was a significant overrepresentation of factors involved in fatty 
acid β -oxidation (p < 0.01). As for genes that were subject to transcriptional downregulation by met-
formin, there was a significant statistical overrepresentation of factors involved in lipid metabolic pro-
cesses (p < 0.05). Notably, several of the genes included in this category have previously been identified 
as transcriptional target genes of SRC-2 (Table  1). We next performed a separate qPCR validation of 
the microarray and overlapping SRC-2 target genes in which FaO hepatoma cells were incubated with 
increasing concentrations of metformin. Combining the annotated genes from Table 1 with other known 
SRC-2 target genes11, we observed that metformin dose-dependently downregulated mRNA levels of 
SRC-2 target genes involved in gluconeogenesis (G6pc), biosynthesis of lipids (Fasn, Elovl6) and choles-
terol (Hmgcr, Hmgcs1, Sqle, Nsdhl, Cyp51 and Egr1) (Fig. 3). In line withour microarray data, we found 
that the insulin receptor (Insr) was upregulated by metformin, and Igfbp, a known metformin-inducible 
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gene30,31, was included as a positive control. In order to verify that these genes indeed represent SRC-2 
target genes we performed transient siRNA knock-down of SRC-2 in FaO cells. Endogenous gene expres-
sion levels of all genes were measured by RT-qPCR 72 hours after siRNA transfection (Fig.  4a). We 
observed that knock-down of SRC-2 reduced G6pc expression and also significantly lowered mRNA 
levels of the included genes relating to lipid and cholesterol biosynthesis, with the only exception of Egr1. 
In the microarray, the Srebp1 gene was omitted due to the unsatisfactory FDR associated with this gene. 
Notably, Srebp1 but not Srebp2 has been previously identified as a SRC-2 target gene11 and we were only 
able to detect a moderate decrease of Srebp1 mRNA in response to knock-down of SRC-2. To validate 
that the observed changes in gene expression were indeed caused by the absence of SRC-2 protein we 
performed Western blot experiments to verify that the knock-down procedure had markedly reduced the 
SRC-2 protein level (Fig. 4b). Taken together, these results indicate that metformin causes transcriptional 
repression of key metabolic genes, of which several represent SRC-2 target genes.
Metformin inhibits recruitment of SRC-2 to target gene promoters. Gene expression is 
preceded by binding of transcriptional activators and associated coactivators that ultimately recruit RNA 
polymerase II (RNAP) to target gene promoters. Bioinformatic analyses using Genomatix, UCSC and 



































































































Figure 1. Metformin inhibits expression of SRC-2. (a) The effect of vehicle (Veh, water) or metformin 
treatment on the endogenous mRNA expression levels of steroid receptor coactivators SRC-1, SRC-2 and 
SRC-3 in FaO hepatoma cells was determined by RT-qPCR. Metformin is known to downregulate G6pc 
expression and this gene was included as a positive control. Target gene expression was normalized to 
reference gene Rpl4 and represented as mean fold change relative to vehicle treatment ± SEM of biological 
triplicates. (b) FaO cells were treated as indicated and biological duplicates of 30 μ g lysate were analyzed 
by Western blotting using antibodies against SRC-2 and ACTB load control. Volumetric densitometry 
band analysis of SRC-2 protein was normalized to ACTB. Data present mean relative SRC-2 protein 
amount ± SEM of biological duplicates in three independent experiments. (c) HepG2 cells were transfected 
with luciferase reporter constructs under transcriptional control of the bases − 1500/+ 1 of the human 
SRC-2 promoter (pGL-SRC-2) or no promoter (pGL-empty). Reporter transactivation was measured 
by luminescence and is presented as the mean ratio between the two constructs, relative to vehicle 
treatment ± SEM of biological triplicates. *p < 0.05; **p < 0.01.
www.nature.com/scientificreports/
4Scientific RepoRts | 5:16430 | DOI: 10.1038/srep16430
binding motif at the proximal promoters of the above SRC-2 target genes, including Srebp1 itself, but 
with the exception of G6pc. On the proximal G6pc promoter, however, it has previously been shown 
that SRC-2 is a coactivator of the nuclear receptor RORα 10. In order to determine whether metformin 
reduces recruitment of SRC-2 to target gene promoters we performed chromatin immunoprecipita-
tion (ChIP) with respect to SRC-2 and RNAP protein and designed qPCR primers to amplify regions 
of proximal SREs of respective target gene promoters. For the G6pc promoter, primers were designed 
to amplify the relevant proximal RORα response element (RORE). Due to the inability of any tested 
Figure 2. Metformin-induced changes in the transcriptome. Based on the significance analysis of 
microarrays, genes that were differentially regulated by metformin were ordered into PANTHER biological 
categories. Only genes exhibiting a fold change (FC) equal to or greater than 1.5 (FC ≥ 1.5; upregulated) or 
equal to or less than − 1.5 (FC ≤ − 1.5; downregulated) and FDR ≤ 0.2 were included. Red and blue cells 
annotate significant overrepresentation of upregulated and downregulated gene categories, respectively.
Gene Description FC Biosynthetic pathway
Elovl6* Elongation of very long chain fatty acids protein 6 − 4.9 Lipid biosynthesis
Fasn* Fatty acid synthase − 2.4 Lipid biosynthesis
Hmgcr* 3-hydroxy-3-methylglutaryl-CoA reductase − 1.7 Cholesterol biosynthesis
Sqle* Squalene monooxygenase − 2.8 Cholesterol biosynthesis
Pigm Phosphatidylinositol glycan anchor biosynthesis class M − 4.6 Glycosylphosphatidyl-inositol biosynthesis
Hsd11b2 Corticosteroid 11-beta-dehydrogenase isozyme 2 − 2.7 Cortisol metabolism
Star Steroidogenic acute regulatory protein − 4.6 Steroid hormone biosynthesis
Gpd1 Glycerol-3-phosphate dehydrogenase − 2.1 Glycerol metabolism
Srd5a1 3-oxo-5-alpha-steroid 4-dehydrogenase 1 − 2.4 Steroid hormone biosynthesis
Fabp2 Fatty acid-binding protein − 4.5 Fatty acid transport
Table 1.  Transcriptional downregulation of lipid metabolic process genes by metformin. Gene entry 
comprising the statistically overrepresented microarray category “lipid metabolic process” (p < 0.05). Genes 
marked with *asterisks indicate previously established SRC-2 target genes11. Downregulation of the indicated 
genes in FaO hepatoma cells after treatment with metformin is annotated by the negative fold change (FC).
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ChIP-grade antibody to immunoprecipitate the rat SRC-2 antigen, HepG2 cells were used for this assay. 
HepG2 cells were incubated with vehicle (water) or metformin (5 mM) for 24 hours and ChIP end-point 
qPCR demonstrated that recruitment of both RNAP and SRC-2 to target gene promoters (G6PC, FASN, 
ELOVL6, HMGCR, HMGCS1, CYP51, NSDHL, SQLE and SREBP1) was significantly reduced upon treat-
ment with metformin (Fig.  5). These results are in agreement with the above findings, that both met-
formin and transient knock-down of SRC-2 reduce expression of the corresponding genes. Notably, the 
levels of unspecific recruitment observed with negative control IgG antibody appeared at very late qPCR 
cycles for all promoters. Thus, the insignificantly small background noise did not influence interpretation 
of results in terms of absolute quantification or by normalization according to the [Ct (Sample)] – [Ct 
(IgG)] subtraction method.
SRC-2 coactivates SREBP-1 at the FASN promoter. In light of the recent discovery that SRC-2 
acts as a coactivator of SREBP-1 in prostate cancer cells32 we wanted to examine whether this also 
occurred in a hepatocellular system. Additionally, we investigated whether SRC-2 could coactivate the 
related SREBP-2. A luciferase reporter construct under transcriptional control of the proximal FASN pro-
moter, containing bases − 220/+ 25 relative to transcription start site, was overexpressed in conjunction 
with full-length SREBPs and SRC-2 in HepG2 cells. The combined overexpression of SREBP-1 and SRC-2 
synergistically stimulated reporter transactivation, suggesting that SRC-2 indeed coactivates SREBP-1 
at the FASN promoter (Fig. 6a). In contrast, this effect was not observed with overexpression of SRC-2 
and SREBP-2, suggesting that SRC-2 does not act as a coactivator for SREBP-2 in this context (Fig. 6b). 
It is plausible that SRC-2 coactivation of SREBP-1 is also relevant with respect to other SREBP-1 target 
gene promoters.
Knock-down of SRC-2 and Srebp1, and treatment with metformin reduces hepatocellular fat 




























Figure 3. Downregulation of SRC-2 and its target genes by metformin. FaO cells were treated for 
24 hours with increasing concentrations of metformin prior to RT-qPCR analysis of endogenous mRNA 
expression levels of the indicated genes. Expression levels of Insr and Igfbp1 were included as positive 
controls of metformin-upregulated genes. Gene expression was normalized to the reference gene Rpl4 
and presented as mean fold change relative to vehicle treatment ± SEM of biological triplicates. One 
representative out of three independent experiments is shown. Where indicated, **p < 0.01.
www.nature.com/scientificreports/
6Scientific RepoRts | 5:16430 | DOI: 10.1038/srep16430
whether the absence of SREBP-1 and its coactivator SRC-2 would affect actual lipogenesis and cellular 
lipid content. Therefore we knocked down Srebp1 and SRC-2 in FaO hepatoma cells and starved the cells 
in serum-free medium for 48 hours prior to re-introduction of supplemented medium for 24 additional 
hours to facilitate lipogenic fat accretion. End-point Oil Red O staining demonstrated that cellular lipid 
content was reduced when Srebp1 and SRC-2 were knocked down simultaneously (Fig. 7a). Optical den-
sity quantitative measurements of the total cellular Oil Red O content confirmed that lipid levels were 
significantly reduced when both Srebp1 and SRC-2 were knocked down (Fig. 7b). We also starved FaO 
cells in serum-free medium for 48 hours prior to reintroduction of supplemented medium containing 
vehicle (water) or 5 mM metformin for 24 additional hours. Subsequent Oil Red O staining (Fig.  7c) 
and optical density quantification (Fig.  7d) demonstrated that cellular lipid contents were significantly 
reduced upon treatment with metformin compared to the vehicle control. These results demonstrate 
that Srebp1 and SRC-2 contribute to stimulate hepatocellular lipogenesis, whereas metformin has an 
inhibitory effect on this same process.
Discussion
Previous studies have demonstrated that hepatic SRC-2 transcriptionally promotes energy-demanding 
pathways including gluconeogenesis and biosynthesis of fatty acids and cholesterol. Here, we demon-
strate that the pharmacological effects of metformin extend to inhibit expression of SRC-2 and, in turn, 
SRC-2 target genes including rate-limiting enzymes pertaining to gluconeogenesis (G6pc) and biosyn-
thesis of lipids (Fasn) and cholesterol (Hmgcr and Hmgcs1). Previously it was shown that SRC-2 can act 

































































































Figure 4. Knock-down of SRC-2 reduces target gene expression. (a) Quantification of endogenous mRNA 
levels of SRC-2 and its target genes in FaO cells were measured by RT-qPCR, 72 hours after transfection 
with non-targeting (white bars) or SRC-2 (black bars) siRNA. Gene expression was normalized to reference 
gene Rpl4 and presented as mean fold change relative to transfection with NT siRNA ± SEM of biological 
triplicates of a representative experiment. (b) Protein levels of SRC-2 and load control ACTB were assessed 
by Western blot 72 hours after transfection of FaO cells with SRC-2 or NT siRNA. Quantification of protein 
bands was determined by densitometry. Data is presented as the relative SRC-2 protein amount ± SEM of 
nine biological replicates, representative of two independent experiments. *p < 0.05; **p < 0.01, ***p< 0.001; 
n.s not significant.
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the AMPK pathway are known to inhibit activity of both mTORC1 and SREBP-116,19. However, several 
pharmacological properties of metformin appear to be mediated independently of the AMPK pathway. 
Interestingly, the ability of metformin to inhibit both gluconeogenic gene expression and mTORC1 activ-
ity is retained in absence of the AMPK enzyme25,26.
Our initial findings show that metformin, in a concentration-dependent manner, causes transcrip-
tional downregulation and thus reduction of the available protein level of SRC-2, and this effect was 
not observed with SRC-1 or SRC-3. Microarray analysis of FaO hepatoma cells treated with or with-
out metformin revealed significant upregulation of genes involved in fatty acid β -oxidation. Conversely, 
there was a significant overrepresentation of downregulated genes associated with lipid biosynthesis, of 
which several were identified as SRC-2 target genes. Combining the latter entry with other metabolically 
relevant and previously established SRC-2 hepatic target genes identified by Jeong et al.11, we show that 
metformin in a dose-dependent manner inhibits transcription of this entire panel of SRC-2 target genes. 
The observed difference in dose responses for these genes is likely due to metformin differentially mod-
ulating the intrinsic activity of a large array of other transcription factors and coregulators on the various 
promoters. In line with the microarray results and the insulin-sensitizing property of metformin, we also 
show that metformin stimulates expression of the insulin receptor (Insr). Furthermore, the stimulating 
effect of metformin on expression of the insulin-like growth factor binding protein 1 (Igfbp1) has been 
described previously30,31. We also demonstrate that transient siRNA knock-down of SRC-2 is sufficient 
to significantly reduce mRNA expression of indicated SRC-2 target genes, with the exception of Early 
growth response 1 (Egr1). Notably, Egr1 has been reported to be a transcriptional target of SRC-211,33 
and is implicated in promotion of obesity and insulin resistance34, progression of prostate cancer35 and 
transcriptional regulation of lipid and cholesterol biosynthetic genes36. Interestingly, Egr1 was mark-
edly downregulated when cells were treated with metformin, and this could potentially be related with 
Vehicle (H2O) Metformin (5 mM)
Figure 5. Recruitment of SRC-2 and RNA polymerase to target gene promoters. Chromatin 
immunoprecipitation of RNA polymerase II (RNAP) and SRC-2 in HepG2 cells treated with vehicle (white 
bars) or 5 mM metformin (black bars). IgG represents assay background noise. Eluted sample DNA was 
subjected to qPCR amplification of regions overlapping known SREBP-1 binding sites at the proximal 
promoters of indicated target genes. For G6Pc, primers were designed to amplify the genomic promoter 
region flanking the proximal RORE. Signal quantification was normalized to that of respective treatment 1% 
input samples and data is presented as mean recruitment (% of input) ± SEM of biological triplicates in one 
representative out of three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001.
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the recent discovery that metformin administration after prostate cancer diagnosis is associated with 
decreased mortality37.
It has previously been shown that SRC-2 coactivates SREBP-1 and we therefore wanted to investigate 
whether the reduced SRC-2 expression and protein level in response to metformin treatment also would 
affect recruitment of SRC-2 to mutual target gene promoters. Sequential recruitment of the general tran-
scription machinery and ultimately RNA polymerase II is a core property of steroid receptor coactivators, 
including SRC-26. Using ChIP analysis we demonstrate that metformin significantly reduces recruitment 
of both endogenous SRC-2 and RNA polymerase II to sterol regulatory elements (SREs) located proxi-
mally at promoters of the entire panel of SRC-2 target genes. Notably, there is no SRE at the human G6Pc 
promoter. However, SRC-2 is a known coactivator of the nuclear receptor RORα on the G6Pc promoter10 
and we observed that recruitment of SRC-2 to the relevant proximal RORα response element (RORE) 
a.
b.
Figure 6. SRC-2 is a coactivator of SREBP-1. Transactivation of a luciferase reporter construct under 
transcriptional control of the endogenous − 220/+ 25 FASN promoter in response to combinatorial 
overexpression of SRC-2 and (a) SREBP-1 or (b) SREBP-2. Data are presented as mean arbitrary luciferase 
units ± SEM of biological quadruplicates. The presence or absence of coactivation synergy is illustrated. 
***p ≤ 0.001; n.s not significant.
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was significantly reduced when cells were treated with metformin. It is well established that transcrip-
tional control of coactivators is essential to the regulation of hepatic gluconeogenesis38. For example, 
the inhibitory effect of metformin and AMPK on the CREB regulated transcription factor 2 (CRTC2/
TORC2) impedes expression of the master gluconeogenic coactivator PGC-1α 39. Our observation that 
metformin inhibits SRC-2 expression is thus reconcilable with the established effect of metformin.
Previous studies have shown that transcription of SREBP-1 is positively regulated by insulin, and 
that metformin inhibits expression of SREBP-1 in vivo40. By downregulating both SREBP-1 expression 
and activity, metformin effectively inhibits lipogenesis and accumulation of hepatic lipids20,40,41. Here, 
we show in a hepatocellular system that SRC-2 is able to coactivate SREBP-1, but not SREBP-2, and 
that also SRC-2 is subject to transcriptional suppression by metformin. Our findings complement the 
established inhibitory effect of metformin on SREBP-1 and provide a new layer of complexity as to how 
metformin suppresses the transcriptional activity of SREBP-1 and lipogenesis. In particular, a key feature 
of SREBP-1 is to mediate expression of FASN which is the rate-limiting enzyme in de novo lipogenesis. 
Whereas knock-down of Srebp1 alone in our system was insufficient to functionally lower hepatocellular 
fat accretion, we observed a marked decline in intracellular fat content upon simultaneous knock-down 
of Srebp1 and SRC-2. This implies that SRC-2 markedly contributes to hepatocellular lipogenesis by 
coactivating SREBP-1. Metformin alone significantly reduced hepatocellular lipogenic fat accumulation, 
and this may partly be due to transcriptional suppression of SRC-2.
In conclusion, we provide evidence that treatment of cells with metformin is accompanied by 
reduced expression of SRC-2, which in turn impedes transcription of gluconeogenic G6Pc and coac-
tivation of SREBP-1 at key metabolic target gene promoters. We propose that the ability of metformin 
Figure 7. Inhibition of hepatocellular fat accretion. (a) Oil Red O staining of FaO hepatoma cells at 40x 
magnification after combinatorial knock-down with non-targeting (NT), SRC-2 and Srebp1 siRNA. Cells 
were starved in serum-free medium for 48 hours prior to introduction of medium supplemented with 10% 
FBS and 2 mM glutamine for 24 additional hours. Scale bar: 25 μ m. (b) Oil Red O staining of FaO cells at 
40x magnification following starvation for 48 hours prior to introduction of medium supplemented with 10% 
FBS, 2 mM glutamine and vehicle (Veh, water) or increasing doses of metformin for 24 additional hours. 
Scale bar: 25 μ m. (c) Quantitative analysis of Oil Red O content of cells from experiment (a) was done by 
measuring optical density of eluate at 490 nm. By convention, total Oil Red O content from cells transfected 
with NT siRNA was defined as 100% and all other samples were normalized accordingly. (d) Quantitative 
analysis of Oil Red O content of cells from the experiment (b). Data are presented as percent mean 
absorbance relative to cells treated with vehicle ± SEM of biological triplicates from one representative out of 
three or more independent experiments. *p < 0.05; **p < 0.01.
www.nature.com/scientificreports/
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to transcriptionally suppress gluconeogenesis and biosynthesis of lipids and cholesterol is in part due to 
transcriptional inhibition of SRC-2.
Methods
Cell culture, transfection and siRNA. Human HepG2 and rat FaO hepatoma cells were purchased 
from ATCC and cultured in a 5% CO2 incubator at 37 °C. The culture media EMEM (Lonza, Basel, 
Switzerland) and F-12 HAM (Gibco, Waltham, MA, USA) were supplemented with 10% fetal bovine 
serum (FBS) (Gibco), 1% penicillin-streptomycin (Sigma, St. Louis, MO, USA) and 2 mM L-glutamine 
(Lonza). Cells were seeded 24 hours prior to transfection to a standardized density of 50.000 cells/24-
well. For indicated experiments, cells were treated for 24 hours with metformin hydrochloride (Sigma) 
dissolved in sterile-filtered water. Transient plasmid transfections were performed in HepG2 cells using 
TransIT-LT1 reagent (Mirus, Madison, WI, USA) according to the manufacturer’s protocol. All plasmids 
were verified by sequencing. The following reporter constructs were used: pGL-basic; pGL-SRC-2 (con-
taining promoter bases − 1500/+ 1) and pFASN-luc (containing promoter bases − 220/+ 25). The fol-
lowing expression vectors were used: pSG5-HA-SRC-2; pSG5-empty; pcDNA3.1-2xFLAG-SREBP-1a and 
pcDNA3.1-2xFLAG-SREBP-2. For knock-down experiments we employed the TransIT-TKO transfection 
reagent (Mirus) with rat SRC-2 (Nuclear receptor coactivator 2) and rat non-targeting (NT) SMARTpool 
ON-TARGETplus siRNA (Dharmacon, Lafayette, CO, USA) at 100 nM final concentration. Cells were 
transfected with siRNA 72 hours prior to further analyses.
Transactivation assays. Cells were lysed with buffer containing 25 mM Tris Acetate-EDTA (pH 7.8), 
2 mM dithiotheitol, 1 mM EDTA, 10% glycerol and 1% Triton X-100 and sample lysate luciferase activ-
ity was analyzed using a luciferase kit (BioThema, Handen, Sweden) and a FLUOStar Optima (BMG 
Labtech, Ortenberg, Germany) luminescence plate reader.
RT-qPCR analysis of gene expression. Cells were lysed in RLT buffer (Qiagen, Hilden, Germarny) 
and processed for RNEasy (Qiagen) RNA isolation according to manufacturer’s protocol. Yield con-
centrations were measured by NanoDrop and 500 ng sample RNA was used for cDNA synthesis using 
High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Waltham, MA, USA) according 
to the manufacturer’s instructions. Synthesized cDNA was diluted 1:10 in water prior to SYBR I Green 
(Roche, Basel, Switzerland) real-time RT-qPCR of target genes relative to reference gene Rpl4. Primer 
sequences are presented in the Supplementary Table S1. Relative target/Rpl4 mRNA quantification was 
calculated using the delta-delta Ct method.
Microarray. FaO cells were treated with metformin (5 mM) or vehicle (water) for 24 hours prior to 
RNEasy (Qiagen) RNA purification. Integrity of total RNA (RIN value ≥ 9.0) from n = 3 biological rep-
licates per treatment was verified by Agilent Bioanalyzer prior to sample randomization and microarray 
(Agilent, Santa Clara, CA, USA) at the Genomics Core Facility, University of Bergen. No sample batch 
effects were observed. Significance analysis of microarrays was performed with J-Express software (http://
jexpress.bioinfo.no/site). Only genes exhibiting a fold-change FC ≤ − 1.5 or FC ≥ 1.5 relative to vehicle 
and false discovery rate (FDR) ≤ 0.2 were included in subsequent analyses. Functional annotations of 
valid genes and statistical overrepresentation of biological categories were retrieved in accordance with 
instructions42 using the PANTHER online database (pantherdb.org). The PANTHER library of 22957 
annotated genes (Rattus norvegicus) was used as reference list for calculating statistical overrepresenta-
tion. Microarray data is included as Supplementary Dataset.
Western blotting. Sample cell lysate (30 μ g) was loaded onto precast 4–20% Mini-Protean TGX 
gels (Bio-Rad, Hercules, CA, USA) and subjected to SDS-PAGE prior to iBlot (Invitrogen, Waltham, 
MA, USA) transfer to nitrocellulose membrane. The following antibodies were used: beta-Actin/ACTB 
(Abcam, Cambridge, UK, cat.no ab8227); SRC-2 (BD Biosciences, San Jose, CA, USA, cat. no 610985); 
HA-HRP (Roche, cat. no 12013819001); HRP goat-anti mouse IgG (BD Biosciences, cat. no 554002); 
HRP goat-anti rabbit IgG (Thermo Scientific, Waltham, MA, USA, cat. no 31460). Immunoblotted mem-
branes were developed using Femto substrate (Thermo Scientific) and analyzed on a ChemiDoc XRS 
imager (Bio-Rad) equipped with QuantityOne densitometry software. For densitometry analyses, volu-
metric protein band intensity was normalized to that of ACTB in the same gel lane.
Chromatin immunoprecipitation (ChIP). Seeding of 2.0 × 106 HepG2 cells per 92 mm plate was 
performed one day prior to treatment with either 5 mM metformin or vehicle (water) for 24 hours. Cells 
were fixated with 1% (v/v) formaldehyde for 10 minutes and further processed using EZ-Magna ChIP 
kit (Millipore, Billerica, MA, USA) in accordance with the manufacturer’s protocol. Sonication was opti-
mized to 8 minutes (30 second on/off cycles) using a cold-water bath Bioruptor (Diagenode, Denville, NJ, 
USA). The following antibodies were used in conjunction with Protein A magnetic beads for over-night 
immunoprecipitation: ChIP-grade anti-RNA Pol II (Millipore #05-623B); normal IgG (Millipore #PP64B); 
ChIP grade anti-SRC-2 (Abcam ab9261) in quantities of 5 μ l per sample. Primers for end-point SYBR 
Green qPCR of eluted sample DNA were designed to amplify regions flanking proximal sterol regulatory 
elements (SREs) at target gene promoters. Primer specificities and SRE motifs were verified in silico using 
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the UCSC Genome Browser (http://genome-euro.ucsc.edu) and Genomatix software. Primer sequences 
are listed in Supplementary Table S2. Quantification of samples by qPCR was normalized to parallel 
qPCR of 1% sonicated lysate input of respective treatments.
Oil Red O lipid staining. Cells were treated as indicated prior to fixation in 4% formaldehyde in PBS 
for 5 minutes followed by 1.5 hours with fresh 4% formaldehyde in PBS. Cells were washed twice with 
sterile water prior to incubation for 5 minutes with 60% isopropanol and being completely dried. Per 
well (12-well format) 1 ml of Oil Red O working solution (0.30 g Oil Red O in 100 ml 99% isopropanol, 
diluted 3:2 with sterile water) was added and left for 20 minutes prior to washing of each well 4 times 
with sterile water. Cells were depicted by Nikon TS100 light microscope and subsequent elution of cel-
lular Oil Red O was done by gently washing of the wells with 1 ml 100% isopropanol. Optical density of 
eluted Oil Red O was measured at 490 nm.
Statistical analyses. Unless indicated otherwise, data values are expressed as Mean ± SEM of three or 
more biological replicates. All experiments were reproduced at least three times. All numerical data pre-
sented was considered to be of normal distribution and statistical differences between mean values were 
evaluated using two-tailed, independent Student’s t-test. Differences of p ≤ 0.05 (indicated*), p ≤ 0.01 
(indicated**) or p ≤ 0.001 (indicated***) were considered significant. GraphPad Prism v5.0 (GraphPad 
Software Inc, La Jolla, CA, USA) was used for statistical calculations and graphical presentation of data.
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